242 related articles for article (PubMed ID: 17985089)
21. [Hereditary neuroendocrine gastroenteropancreatic tumors and multiple endocrine neoplasia type 1. I. Diagnosis].
Scherübl H; Schaaf L; Raue F; Faiss S; Zeitz M
Dtsch Med Wochenschr; 2004 Mar; 129(12):630-3. PubMed ID: 15011133
[No Abstract] [Full Text] [Related]
22. The various faces of autoimmune endocrinopathies: non-tumoral hypergastrinemia in a patient with lymphocytic colitis and chronic autoimmune gastritis.
Melcescu E; Hogan RB; Brown K; Boyd SA; Abell TL; Koch CA
Exp Mol Pathol; 2012 Dec; 93(3):434-40. PubMed ID: 23043903
[TBL] [Abstract][Full Text] [Related]
23. Management of Gastric Neuroendocrine Tumors: A Review.
Sok C; Ajay PS; Tsagkalidis V; Kooby DA; Shah MM
Ann Surg Oncol; 2024 Mar; 31(3):1509-1518. PubMed ID: 38062290
[TBL] [Abstract][Full Text] [Related]
24. Regular chromogranin A monitoring facilitated the early detection of a gastrointestinal neuroendocrine tumour in a patient with type 1 diabetes.
Herold Z; Uhlyarik A; Herold M; Nagy P; Huszty GD; Rosta K; Doleschall M; Somogyi A
Endokrynol Pol; 2020; 71(5):483-484. PubMed ID: 32856287
[TBL] [Abstract][Full Text] [Related]
25. Sporadic versus hereditary gastrinomas of the duodenum and pancreas: distinct clinico-pathological and epidemiological features.
Anlauf M; Garbrecht N; Henopp T; Schmitt A; Schlenger R; Raffel A; Krausch M; Gimm O; Eisenberger CF; Knoefel WT; Dralle H; Komminoth P; Heitz PU; Perren A; Klöppel G
World J Gastroenterol; 2006 Sep; 12(34):5440-6. PubMed ID: 17006979
[TBL] [Abstract][Full Text] [Related]
26. Gastrinoma: advances in localization and treatment.
Norton JA
Surg Oncol Clin N Am; 1998 Oct; 7(4):845-61. PubMed ID: 9735137
[TBL] [Abstract][Full Text] [Related]
27. Zollinger-Ellison syndrome. Advances in treatment of gastric hypersecretion and the gastrinoma.
Jensen RT; Fraker DL
JAMA; 1994 May; 271(18):1429-35. PubMed ID: 7513768
[No Abstract] [Full Text] [Related]
28. [Neuroendocrine tumors of the digestive system].
Prónai L; Rácz K; Tulassay Z
Orv Hetil; 2002 May; 143(19 Suppl):1081-6. PubMed ID: 12063866
[TBL] [Abstract][Full Text] [Related]
29. [Inherited tumor syndromes of gastroenteropancreatic and thoracic neuroendocrine neoplasms].
Couvelard A; Scoazec JY
Ann Pathol; 2020 Apr; 40(2):120-133. PubMed ID: 32035641
[TBL] [Abstract][Full Text] [Related]
30. Duodenal neuroendocrine neoplasms: a still poorly recognized clinical entity.
Rossi RE; Rausa E; Cavalcoli F; Conte D; Massironi S
Scand J Gastroenterol; 2018; 53(7):835-842. PubMed ID: 29726295
[TBL] [Abstract][Full Text] [Related]
31. Diagnosis and treatment of gastrinoma in the era of proton pump inhibitors.
Banasch M; Schmitz F
Wien Klin Wochenschr; 2007; 119(19-20):573-8. PubMed ID: 17985090
[TBL] [Abstract][Full Text] [Related]
32. [Diagnostic and therapeutic difficulties in MEN 1 syndrome].
Krassowski J
Endokrynol Pol; 2005; 56(3):302-7. PubMed ID: 16350723
[TBL] [Abstract][Full Text] [Related]
33. Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior.
Rindi G; Bordi C; Rappel S; La Rosa S; Stolte M; Solcia E
World J Surg; 1996 Feb; 20(2):168-72. PubMed ID: 8661813
[TBL] [Abstract][Full Text] [Related]
34. Management of carcinoid tumors of the stomach, duodenum, and pancreas.
Akerström G
World J Surg; 1996 Feb; 20(2):173-82. PubMed ID: 8661814
[TBL] [Abstract][Full Text] [Related]
35. [Diagnostics and treatment in functional pancreatic neuroendocrine tumours].
Müssig K; Dudziak K; Horger M; Anlauf M; Goretzki PE
Dtsch Med Wochenschr; 2011 Jun; 136(24):1319-30. PubMed ID: 21656454
[TBL] [Abstract][Full Text] [Related]
36. [Oesophageal and gastric pathology: early neoplastic lesions: case n(o) 8: an endocrine tumour of the stomach].
Scoazec JY
Ann Pathol; 2011 Oct; 31(5):390-5. PubMed ID: 21982248
[No Abstract] [Full Text] [Related]
37. Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis.
Moore AR; Boyce M; Steele IA; Campbell F; Varro A; Pritchard DM
PLoS One; 2013; 8(10):e76462. PubMed ID: 24098507
[TBL] [Abstract][Full Text] [Related]
38. Diagnosis of functioning pancreaticoduodenal neuroendocrine tumors.
Imamura M; Nakamoto Y; Uose S; Komoto I; Awane M; Taki Y
J Hepatobiliary Pancreat Sci; 2015 Aug; 22(8):602-9. PubMed ID: 25624017
[TBL] [Abstract][Full Text] [Related]
39. Histologic changes in type A chronic atrophic gastritis indicating increased risk of neuroendocrine tumor development: the predictive role of dysplastic and severely hyperplastic enterochromaffin-like cell lesions.
Vanoli A; La Rosa S; Luinetti O; Klersy C; Manca R; Alvisi C; Rossi S; Trespi E; Zangrandi A; Sessa F; Capella C; Solcia E
Hum Pathol; 2013 Sep; 44(9):1827-37. PubMed ID: 23642738
[TBL] [Abstract][Full Text] [Related]
40. Clinicopathologic aspects of gastric neuroendocrine tumors.
Rindi G
Am J Surg Pathol; 1995; 19 Suppl 1():S20-9. PubMed ID: 7762736
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
